N-phenylacetylvaline | 2752-50-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-phenylacetylvaline
• 英文别名: phenylacetylvaline；N-phenylacetyl-DL-valine；N-Phenylacetyl-DL-valin；N-phenylacetylated valine；N-(phenylacetyl)valine；(+/-)-N-(Phenylacetyl)-valin；3-Methyl-2-(2-phenylacetamido)butanoic acid；3-methyl-2-[(2-phenylacetyl)amino]butanoic acid
• CAS: 2752-50-3
• 化学式: C₁₃H₁₇NO₃
• mdl: MFCD00451539
• 分子量: 235.283
• InChiKey: FJGOZOLLBLTSIJ-UHFFFAOYSA-N

物化性质

• 熔点：
  115 °C
• 沸点：
  469.5±38.0 °C(Predicted)
• 密度：
  1.141±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.384
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-phenylacetylvaline 在 silica gel-supported piperidine 作用下， 以 二氯甲烷 为溶剂， 反应 2.25h， 生成
  参考文献：
  名称：

  1-（N-酰基氨基）烷基三芳基phosph盐与富电子芳烃的无催化剂Friedel-Crafts反应

  摘要：

  1-（N-酰基氨基）烷基三芳基phosph盐与芳烃或杂芳烃的Friedel-Crafts反应，不需要任何催化剂，提供了广泛的生物学意义上的N-（1-芳基烷基）酰胺或1-芳基烷基phosph盐的接触途径。对叶立德和phospho离子液体的化学非常感兴趣。取决于反应条件和底物结构，反应可以选择性地以高收率朝向上述每种产物进行。还考虑了上述转换的机械方面。

  DOI：

  10.1016/j.tet.2018.03.053
• 作为产物：
  描述：

  苯乙酰氯 、 D,L-valine 以 sodium hydroxide 、 乙醚 为溶剂， 以69%的产率得到N-phenylacetylvaline
  参考文献：
  名称：

  Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds

  摘要：

  公开了抑制β-淀粉样肽释放和/或其合成的化合物，因此可用于治疗阿尔茨海默病。还公开了包含抑制β-淀粉样肽释放和/或其合成的化合物的药物组合物，以及使用这些药物组合物预防性和治疗性地治疗阿尔茨海默病的方法。

  公开号：

  US06506782B1

文献信息

• [EN] COSMETIC USES AND METHODS FOR INDOLINE GRANZYME B INHIBITOR COMPOSITIONS<br/>[FR] UTILISATIONS ET PROCÉDÉS COSMÉTIQUES POUR DES COMPOSITIONS D'INHIBITEUR D'INDOLINE GRANZYME B
  申请人：VIDA THERAPEUTICS INC

  公开号：WO2014153667A1

  公开（公告）日：2014-10-02

  Cosmetic uses and methods for indoline granzyme B inhibitor compounds in compositions with a cosmetically acceptable carrier. Uses and methods for treating, reducing or inhibiting the appearance of ageing in the skin are provided. Also provided are compositions and formulation for cosmetic uses and methods of maintaining a youthful appearance, reducing an appearance of ageing, inhibiting an appearance of ageing, reducing a rate of an appearance of ageing, reducing a skin inelasticity, reducing a rate of increasing skin inelasticity, maintaining a skin elasticity, and increasing the density of hair follicles of a skin of a subjecl. The uses and methods comprise applying/administering an indoline granzyme B inhibitor to a skin, or a portion of a skin of the subject.

  使用和方法用于在与化妆品可接受载体混合的化合物中使用吲哚啶颗粒酶B抑制剂。提供了用于治疗、减少或抑制皮肤衰老的用途和方法。还提供了用于化妆品用途的组合物和配方，以及保持年轻外观、减少衰老外观、抑制衰老外观、减少衰老外观速率、减少皮肤无弹性、减少增加皮肤无弹性速率、保持皮肤弹性和增加皮肤毛囊密度的方法。这些用途和方法包括将吲哚啶颗粒酶B抑制剂涂抹/施用于皮肤或受试者皮肤的部分。
• [EN] GRANZYME B DIRECTED IMAGING AND THERAPY<br/>[FR] IMAGERIE DU GRANZYME B ET THÉRAPIE DIRIGÉES CONTRE LE GRANZYME B
  申请人：CYTOSITE BIOPHARMA INC

  公开号：WO2019160916A1

  公开（公告）日：2019-08-22

  Provided herein are heterocyclic compounds useful for imaging Granzyme B. Methods of imaging Granzyme B, combination therapies, and kits comprising the Granzyme B imaging agents are also provided.

  本文提供了用于成像Granzyme B的杂环化合物。还提供了成像Granzyme B的方法、联合疗法以及包含Granzyme B成像试剂的试剂盒。
• Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
  申请人：——

  公开号：US20020045747A1

  公开（公告）日：2002-04-18

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  公开了抑制β-淀粉样肽释放和/或其合成的化合物，因此可用于治疗阿尔茨海默病。还公开了包含抑制β-淀粉样肽释放和/或其合成的化合物的药物组合物，以及使用这些药物组合物预防性和治疗性治疗阿尔茨海默病的方法。
• [EN] AZAINDOLINE COMPOUNDS AS GRANZYME B INHIBITORS<br/>[FR] COMPOSÉS D'INDOLINE EN TANT QU'INHIBITEURS DU GRANZYME B
  申请人：VIDA THERAPEUTICS INC

  公开号：WO2016015159A1

  公开（公告）日：2016-02-04

  Azaindoline compounds as granzyme B inhibitors, compositions that include the compounds, and methods for using the compounds. Methods for treating cutaneous scleroderma, epidermolysis bullosa, radiation dermatitis, alopecia areata, and discoid lupus erythematosus are provided.

  Azaindoline化合物作为颗粒酶B抑制剂，包含这些化合物的组合物，以及使用这些化合物的方法。提供了治疗皮肤硬化症、表皮溃疡、放射性皮炎、斑秃和圆盘状红斑狼疮的方法。
• [EN] PROCESS FOR PRODUCING AMINO ACID DERIVATIVES<br/>[FR] PROCEDE DE PRODUCTION DE DERIVES D'ACIDES AMINES
  申请人：SOLVAY

  公开号：WO2004087638A1

  公开（公告）日：2004-10-14

  Process for producing amino acid derivatives, in which (a) an organic amine, the amino functionality of which is protected, or an α-amino acid, the amino functionality of which is protected, is subjected to an electrochemical reaction so as to form an amine which is activated in the α-position; (b) the activated amine is subjected to a reaction with a carbanionic reagent containing at least 3 carbon atoms and comprising an unsaturated group so as to form an unsaturated amine comprising an unsaturated group, the atom of the unsaturated group closest to the nitrogen being separated from the nitrogen by at least 2 carbon atoms; (c) the unsaturated amine is subjected to oxidation of the unsaturated group so as to form an amino acid derivative.

  生产氨基酸衍生物的过程，其中（a）将保护氨基官能团的有机胺或保护氨基官能团的α-氨基酸经电化学反应，形成在α位激活的胺；（b）将激活的胺与至少含有3个碳原子且包含不饱和基团的碳负离子试剂反应，形成含有不饱和基团的不饱和胺，最接近氮的不饱和基团原子与氮之间至少相隔2个碳原子；（c）将不饱和胺氧化，形成氨基酸衍生物。